



Neue Trends bei 4MRGN/CPE zwischen 2020-2022






Einsendungen pro Halbjahr



Enterobakterien 2022






Weitere Daten bei Stämmen mit NDM-1


- **Häufig in Kombination mit zweiter Carbapenemase**
 - OXA-48
 - KPC
- **Anamnese häufiger Kriegsverletzung in Ukraine**





K.pneumoniae NDM-1 2022





K.pneumoniae NDM-1 2022







ST 307



ST 395





Rapid communication

Increase in NDM-1 and NDM-1/OXA-48-producing *Klebsiella pneumoniae* in Germany associated with the war in Ukraine, 2022 | 

Check for updates

Mirco Sandfort^{1,*} , Jörg B Hans^{2,*}, Martin A Fischer^{3,*}, Felix Reichert¹ , Martina Cremanns², Jessica Eisfeld², Yvonne Pfeifer³, Annika Heck¹, Tim Eckmanns¹, Guido Werner³, Sören Gatermann², Sebastian Haller^{1,**}, Niels Pfennigwerth^{2,**}

[View Affiliations](#)[View Citation](#)

Open Access

Like

0



Download

[Receive the Table of contents](#)[Create account / Sign-in ▾](#)

Submit your article here

[Submit an Article](#)

Share




Therapieoptionen


Colistin häufig noch ≤ 2 mg/l

Tigecyclin auch häufig ≤ 0.5 mg/l


Cefiderocol häufig in der
ATU




K.pneumoniae OXA-181 2022



K.pneumoniae OXA-181 2022



Doppelcarbapenemasen



2022:
Meist NDM-1 plus OXA-48
dann NDM-5 plus OXA-48

Wirksamkeit neuer Antibiotika bei Stämmen mit OXA-48/-181, NDM-1 und VIM-1

	OXA-48	OXA-181	NDM-1	VIM-1
Ceftazidim-Avibactam	83%	90%	<1%	2%
Meropenem-Vaborbactam	45%	73%	1%	8%
Cefiderocol	62%	62%	6,5%	25%



Wirksamkeit neuer Antibiotika bei Stämmen mit OXA-48/-181, NDM-1 und VIM-1

	OXA-48	OXA-181	NDM-1	VIM-1
Ceftazidim-Avibactam	83%	90%	<1%	2%
Meropenem-Vaborbactam	45%	73%	1%	8%
Cefiderocol	62%	62%	6,5%	25%

Kombination von Aztreonam – Ceftazidim – Avibactam
bei 100 Stämmen mit Doppelcarbapenemase, mindestens eine
MBL bei 99% sicher synergistisch.



Wirksamkeit neuer Antibiotika bei Stämmen mit OXA-48/-181, NDM-1 und VIM-1

	OXA-48	OXA-181	NDM-1	VIM-1
Ceftazidim-Avibactam	83%	90%	<1%	2%
Meropenem-Vaborbactam	45%	73%	1%	8%
Cefiderocol	62%	62%	6,5%	25%





Nationales Referenzzentrum für gramnegative Krankenhauskeime

RUHR
UNIVERSITÄT
BOCHUM

RUB